Atria Investments Inc Buys 7,856 Shares of Zoetis Inc. $ZTS

Atria Investments Inc grew its stake in Zoetis Inc. (NYSE:ZTS) by 8.4% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 100,840 shares of the company’s stock after buying an additional 7,856 shares during the quarter. Atria Investments Inc’s holdings in Zoetis were worth $15,726,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Nova Wealth Management Inc. acquired a new position in Zoetis in the 1st quarter worth $25,000. 1248 Management LLC acquired a new position in shares of Zoetis during the first quarter worth about $27,000. Saudi Central Bank bought a new position in shares of Zoetis during the first quarter worth about $29,000. REAP Financial Group LLC raised its position in Zoetis by 201.5% in the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after buying an additional 131 shares during the last quarter. Finally, Cornerstone Planning Group LLC lifted its stake in Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after acquiring an additional 88 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Trading Down 1.0%

Shares of NYSE:ZTS opened at $143.97 on Thursday. Zoetis Inc. has a 52-week low of $139.34 and a 52-week high of $183.81. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The company has a market capitalization of $63.80 billion, a P/E ratio of 24.78, a price-to-earnings-growth ratio of 2.34 and a beta of 0.90. The company has a 50-day simple moving average of $147.63 and a 200 day simple moving average of $153.48.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same quarter in the prior year, the company earned $1.56 earnings per share. The business’s revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.4%. The ex-dividend date is Friday, October 31st. Zoetis’s payout ratio is currently 34.42%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ZTS. Piper Sandler raised their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Leerink Partnrs cut shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. UBS Group decreased their price objective on Zoetis from $165.00 to $158.00 and set a “neutral” rating for the company in a report on Monday, October 20th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Finally, Argus reaffirmed a “buy” rating and set a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Four equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, Zoetis currently has an average rating of “Hold” and an average target price of $195.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.